CVSCVS HEALTH Corp

NYSE cvshealth.com


$ 60.28 $ 0.38 (0.63 %)    

Thursday, 13-Jun-2024 14:31:10 EDT
QQQ $ 476.70 $ -0.88 (-0.18 %)
DIA $ 386.90 $ 0.02 (0.01 %)
SPY $ 542.18 $ -0.93 (-0.17 %)
TLT $ 93.69 $ 0.50 (0.53 %)
GLD $ 212.85 $ -1.57 (-0.73 %)
$ 59.99
$ 59.91
$ 60.28 x 100
$ 60.31 x 110
$ 59.11 - $ 60.48
$ 52.77 - $ 81.71
10,617,899
na
76.01B
$ 0.77
$ 10.38
TBD
na
na ($ 0.04)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-01-2024 03-31-2024 10-Q
2 02-07-2024 12-31-2023 10-K
3 11-01-2023 09-30-2023 10-Q
4 08-02-2023 06-30-2023 10-Q
5 05-03-2023 03-31-2023 10-Q
6 02-08-2023 12-31-2022 10-K
7 11-02-2022 09-30-2022 10-Q
8 08-03-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-09-2022 12-31-2021 10-K
11 11-03-2021 09-30-2021 10-Q
12 08-04-2021 06-30-2021 10-Q
13 05-04-2021 03-31-2021 10-Q
14 02-16-2021 12-31-2020 10-K
15 11-06-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-06-2020 03-31-2020 10-Q
18 02-18-2020 12-31-2019 10-K
19 11-06-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-01-2019 03-31-2019 10-Q
22 02-28-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 08-08-2018 06-30-2018 10-Q
25 05-02-2018 03-31-2018 10-Q
26 02-14-2018 12-31-2017 10-K
27 11-06-2017 09-30-2017 10-Q
28 08-08-2017 06-30-2017 10-Q
29 05-02-2017 03-31-2017 10-Q
30 02-09-2017 12-31-2016 10-K
31 11-08-2016 09-30-2016 10-Q
32 08-02-2016 06-30-2016 10-Q
33 05-03-2016 03-31-2016 10-Q
34 02-09-2016 12-31-2015 10-K
35 10-30-2015 09-30-2015 10-Q
36 08-04-2015 06-30-2015 10-Q
37 05-01-2015 03-31-2015 10-Q
38 02-10-2015 12-31-2014 10-K
39 11-04-2014 09-30-2014 10-Q
40 08-05-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cantor-fitzgerald-reiterates-neutral-on-cvs-health-maintains-58-price-target

Cantor Fitzgerald analyst Sarah James reiterates CVS Health (NYSE:CVS) with a Neutral and maintains $58 price target.

 abbvies-arthritis-drug-humira-retains-market-dominance-despite-biosimilar-competition-challenges-biosimilar-industry-viability

Humira maintains over 80% of its market share despite facing nine biosimilar rivals, raising concerns about the future of the b...

 how-to-earn-500-a-month-from-cvs-health-stock

CVS Health currently has a dividend yield of 4.38%, which is a quarterly dividend amount of 66.5 cents a share ($2.66 a year).

 jp-morgan-maintains-overweight-on-cvs-health-lowers-price-target-to-86

JP Morgan analyst Lisa Gill maintains CVS Health (NYSE:CVS) with a Overweight and lowers the price target from $101 to $86.

 baird-initiates-coverage-on-cvs-health-with-neutral-rating-announces-price-target-of-61

Baird analyst Michael Ha initiates coverage on CVS Health (NYSE:CVS) with a Neutral rating and announces Price Target of $61.

 are-boomers-crashing-the-economy-or-saving-it-why-investors-are-perplexed-and-what-you-can-do-to-prepare

Mass retirement of boomers could have major economic impact. Experts anticipate both risks and opportunities from the largest w...

 cvs-health-seeks-private-equity-partner-for-oak-street-health-expansion

CVS Health seeks a private equity partner to fund the expansion of Oak Street Health, acquired for $10.6 billion. This joint ve...

 cvs-reportedly-seeking-investor-to-back-new-oak-street-clinics

- Bloomberg

 unitedhealths-optumrx-unveils-new-transparent-drug-pricing-initiative-for-2024

UnitedHealth's OptumRx will implement a new pricing model, OptumRx Clear Trend Guarantee, starting next year.